Last reviewed · How we verify
Market-approved OAC
Market-approved OAC is a Small molecule drug developed by Boston Scientific Corporation. It is currently in Phase 1 development.
At a glance
| Generic name | Market-approved OAC |
|---|---|
| Sponsor | Boston Scientific Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (NA)
- Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation (NA)
- Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control
- COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Market-approved OAC CI brief — competitive landscape report
- Market-approved OAC updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI
Frequently asked questions about Market-approved OAC
What is Market-approved OAC?
Market-approved OAC is a Small molecule drug developed by Boston Scientific Corporation.
Who makes Market-approved OAC?
Market-approved OAC is developed by Boston Scientific Corporation (see full Boston Scientific Corporation pipeline at /company/boston-scientific-corporation).
What development phase is Market-approved OAC in?
Market-approved OAC is in Phase 1.
Related
- Manufacturer: Boston Scientific Corporation — full pipeline
- Compare: Market-approved OAC vs similar drugs
- Pricing: Market-approved OAC cost, discount & access